WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 205842
Description: GLPG0187 is a small molecule integrin receptor antagonist (IRA) with potential antineoplastic activity. Upon administration, GLPG0187 binds to and blocks the activity of 5 RGD-integrin receptor subtypes, including alphavbeta1, alphavbeta3, alphavbeta5, alphavbeta6 and alpha5beta1. This may result in the inhibition of endothelial cell-cell interactions and endothelial cell-matrix interactions, and the prevention of angiogenesis and metastasis in tumor cells expressing these integrin receptors. Integrin receptors are transmembrane glycoproteins expressed on the surface of tumor vessel endothelial cells and some types of cancer cells, and play a crucial role in endothelial cell adhesion and migration.
MedKoo Cat#: 205842
Chemical Formula: C29H37N7O5S
Exact Mass: 595.2577
Molecular Weight: 595.719
Elemental Analysis: C, 58.47; H, 6.26; N, 16.46; O, 13.43; S, 5.38
GLPG0187, purity > 98%, is in stock. The same day shipping out after order is received. .
Synonym: GLPG0187; GLPG 0187; GLPG-0187
IUPAC/Chemical Name: (S)-3-((2,5-dimethyl-6-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)piperidin-1-yl)pyrimidin-4-yl)amino)-2-((4-methoxyphenyl)sulfonamido)propanoic acid.
InChi Key: CXHCNOMGODVIKB-VWLOTQADSA-N
InChi Code: InChI=1S/C29H37N7O5S/c1-18-26(31-17-25(29(37)38)35-42(39,40)23-9-7-22(41-3)8-10-23)32-19(2)33-28(18)36-15-12-20(13-16-36)24-11-6-21-5-4-14-30-27(21)34-24/h6-11,20,25,35H,4-5,12-17H2,1-3H3,(H,30,34)(H,37,38)(H,31,32,33)/t25-/m0/s1
SMILES Code: O=C(O)[C@H](CNC1=NC(C)=NC(N2CCC(C3=NC4=C(CCCN4)C=C3)CC2)=C1C)NS(=O)(C5=CC=C(OC)C=C5)=O
The following data is based on the product molecular weight 595.719 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: van der Horst G, van den Hoogen C, Buijs JT, Cheung H, Bloys H, Pelger RC, Lorenzon G, Heckmann B, Feyen J, Pujuguet P, Blanque R, ClÃ©ment-Lacroix P, van der Pluijm G. Targeting of α(v)-integrins in stem/progenitor cells and supportive microenvironment impairs bone metastasis in human prostate cancer. Neoplasia. 2011 Jun;13(6):516-25. PubMed PMID: 21677875; PubMed Central PMCID: PMC3114245.
GalapagosÂ’ candidate drug, GLPG0187, is an integrin receptor antagonist (IRA) that binds to six integrin receptors known to be present in many metastatic cancers, affording a unique anti-integrin profile. In animal studies, oral administration of GLPG0187 as a single agent has been shown to inhibit multiple processes involved in the spread and growth of metastatic tumors. GLPG0187 therefore offers a new approach to treat metastases, a severe complication of many cancers. In the first-in-human trial, GLPG0187 showed good safety and a promising biomarker profile in healthy volunteers. Based on these results, Galapagos initiated a Phase Ib study in March 2011. In this Phase Ib study, Galapagos plans to assess the safety and explore the preliminary efficacy of GLPG0187 in cancer patients. (source: http://www.glpg.com/index.php/randd/pipeline/glpg0187-cancer/).